3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Myeloid
1
CNS
1
Conditions
Neuroblastoma
7
Lymphoma, B-Cell
5
Lymphoma
5
Rhabdoid Tumor
3
Neoplasms
3
Medulloblastoma
3
Leukemia, Myeloid, Acute
3
Leukemia
3
Sarcoma, Ewing
2
Rhabdomyosarcoma
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Pinealoma
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Neoplasms, Germ Cell and Embryonal
2
Myelodysplastic Syndromes
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Large B-Cell, Diffuse
2
Immunoblastic Lymphadenopathy
2
Hodgkin Disease
2
Ganglioneuroblastoma
2
Ependymoma
2
Enteropathy-Associated T-Cell Lymphoma
2
Brain Neoplasms
2
Solid Tumor
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Recurrence
1
Pyloric Stenosis, Hypertrophic
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Osteosarcoma
1
Interventions
Magnetic Resonance Spectroscopy
7
X-Rays
6
Specimen Handling
6
Phantoms, Imaging
6
Nuclear Medicine Department, Hospital
5
Biopsy
5
ulixertinib
2
trametinib
2
tipifarnib
2
tazemetostat
2
selpercatinib
2
palbociclib
2
larotrectinib
2
ivosidenib
2
erdafitinib
2
ensartinib
2
dabrafenib
2
LY3023414
2
olaparib
1
etoposide phosphate
1
cobimetinib
1
Vemurafenib
1
Sirolimus
1
Pharmacogenomic Variants
1
Lenalidomide
1
Genetic Testing
1
Etoposide
1
Cyclophosphamide
1
Celecoxib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Histiocytosis, Langerhans-Cell
×
etoposide phosphate
×
1 year
×
Clear all
NCT02574728
2026-03-02
AflacST1502
Emory University
Phase 2
Active not recruiting
46 enrolled